NCT04558346View on ClinicalTrials.gov

Ghrelin (OXE--103) for Acute Concussion Management

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

October 30, 2022

Study Completion Date

October 30, 2022

Conditions
Concussion, BrainTraumatic Brain Injury
Interventions
DRUG

Ghrelin (OXE-103)

40ug/kg twice daily by self-injection

DRUG

Placebo

40ug/kg twice daily by self-injection

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
collaborator

University of Kansas Health System

OTHER

collaborator

University of Kansas Medical Center

OTHER

lead

Michael Rippee

OTHER

NCT04558346 - Ghrelin (OXE--103) for Acute Concussion Management | Biotech Hunter | Biotech Hunter